Effects of serum on in vitro susceptibility testing of echinocandins

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 11, 2007, Pages 4214-4216

  Odabasi, Zekaver ^a   Paetznick, Victor ^b   Rex, John H ^b,c   Ostrosky Zeichner, Luis ^b  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b UNIVERSITY OF TEXAS   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; MICAFUNGIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; ASPERGILLUS; CANDIDA; DRUG PROTEIN BINDING; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SERUM;

ASPERGILLUS; CANDIDA; ECHINOCANDINS; HUMANS; LIPOPROTEINS; MICROBIAL SENSITIVITY TESTS; PROTEIN BINDING; SERUM;

EID: 35848946410     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01589-06     Document Type: Article

References (18)

1. Barry, A. L., M. A. Pfaller, S. D. Brown, A. Espinel-Ingroff, M. A. Ghannoum, C. Knapp, R. P. Rennie, J. H. Rex, and M. G. Rinaldi. 2000. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J. Clin. Microbiol. 38:3457-3459.
2. Bartizal, K., C. J. Gill, G. K. Abruzzo, A. M. Flattery, L. Kong, P. M. Scott, J. G. Smith, C. E. Leighton, A. Boulfard, J. F. Dropinski, and J. Balkovec. 1997. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41:2326-2332.
3. Chiller, T., K. Farrokhshad, E. Brummer, and D. A. Stevens. 2000. Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus. Antimicrob. Agents Chemother. 44:3302-3305.
4. Ernst, E. J., E. E. Roling, C. R. Petzold, D. J. Keele, and M. E. Klepser. 2002. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob. Agents Chemother. 46:3846-3853.
5. Hajdu, R., R. Thompson, J. G. Sundelof, B. A. Pelak, F. A. Boulfard, J. F. Dropinski, and H. Kropp. 1997. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41:2339-2344.
6. Heykants, J., M. Michiels, W. Meuldermans, J. Monbaliu, K. Lavrijsen, A. Van Peer, J. C. Levron, R. Woestenborghs, and G. Cauwenbergh. 1987. The pharmacokinetics of itraconazole in animals and man: an overview, p. 1-29. In R. A. Fromtling (ed.), Recent trends in the discovery, development and evaluation of antifungal agents. J. R. Prous Science Publishers, Barcelona, Spain.
7. Kurtz, M. B., I. B. Heath, J. Marrinan, S. Dreikorn, J. Onishi, and C. Douglas. 1994. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob. Agents Chemother. 38:1480-1489.
8. Machard, B., P. Misslin, and M. Lemaire. 1989. Influence of plasma protein binding on the brain uptake of an antifungal agent, terbinafine, in rats. J. Pharm. Pharmacol. 41:700-704.
9. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard NCCLS document M38-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
10. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard NCCLS document M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
11. Ryder, N. S., and I. Frank. 1992. Interaction of terbinafine with human serum and serum proteins. J. Med. Vet. Mycol. 30:451-460.
12. Schafer-Korting, M., H. C. Korting, F. Amann, R. Peuser, and A. Lukacs. 1991. Influence of albumin on itraconazole and ketoconazole antifungal activity: results of a dynamic in vitro study. Antimicrob. Agents Chemother. 35:2053-2056.
13. Schafer-Korting, M., H. C. Korting, W. Rittler, and W. Obermuller. 1995. Influence of serum protein binding on the in vitro activity of anti-fungal agents. Infection 23:292-297.
14. Schmitt, H. J., J. Andrade, F. Edwards, Y. Niki, E. Bernard, and D. Armstrong. 1990. Inactivity of terbinafine in a rat model of pulmonary aspergillosis. Eur. J. Clin. Microbiol. Infect. Dis. 9:832-835.
15. Suzuki, S., M. Terakawa, F. Yokobayashi, F. Fujiwara, and T. Hata. 1998. Pharmacokinetics of FK463, a novel water-soluble echinocandin-like lipopeptide, in animals, abstr. F-144, p. 269. Abstr. 38th Intersci. Conf. Antimicrob. Agents Chemother., San Diego, CA.
16. Tawara, S., F. Ikeda, K. Maki, Y. Morishita, K. Otomo, N. Teratani, T. Goto, M. Tomishima, H. Ohki, A. Yamada, K. Kawabata, H. Takasugi, K. Sakane, H. Tanaka, F. Matsumo, and S. Kuwahara. 2000. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother. 44:57-62.
17. Wise, R. 1985. The relevance of pharmacokinetics to in-vitro models: protein binding-does it matter? J. Antimicrob. Chemother. 15(Suppl. A):77-83.
18. Wright, K. A., J. R. Perfect, and W. Ritter. 1990. The pharmacokinetics of BAY R3783 and its efficacy in the treatment of experimental cryptococcal meningitis. J. Antimicrob. Chemother. 26:387-397.